Gilead Sciences Moves to Acquire Ouro Medicines, Strengthening Its Autoimmune and Inflammation Pipeline with Innovative T-Cell Engager Technology Gilead Sciences has announced a major strategic step to expand its presence…
Biocytok and Moonlight Bio Collaborate to Advance Cell Therapy with Fully Human Antibody Library Biocytogen (Beijing) Pharmaceutical Technology a globally focused biotechnology company known for its innovative platforms in drug…
Aptar’s Introduction to INNA-051 Investigational Nasal Spray AptarGroup a global leader in drug delivery, dosing, and protection technologies, has announced the use of its Unidose (UDS) Powder Nasal Spray System…
Exact Sciences Highlights Advances in MRD and Multi-Cancer Early Detection at AACR 2026 Exact Sciences Corp. is set to present significant new data at the AACR Annual Meeting 2026, underscoring…
United Therapeutics Corporation Shares TETON-2 Phase 3 Trial Findings in The New England Journal of Medicine United Therapeutics Corporation announced that the complete findings from its Phase 3 TETON-2 clinical…
IFF Expands Production and Innovation Capabilities in Latin America with New Enzyme Hub and Applications Laboratory Global ingredients and biosciences leader IFF is strengthening its footprint in Latin America through…
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for…
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus Mirum Pharmaceuticals, Inc. a leading rare disease company, today announced completion of enrollment in the Phase…
HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market HeartBeam, Inc. a medical technology company focused on transforming cardiac care by providing powerful…
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function Seaport…
ARPA-H Awards Up to $15 Million to Seaport Therapeutics and Monash Institute to Advance First Oral Therapy Targeting Gut Lymphatic Dysfunction Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on developing…
Patent Expands Niagen’s Leadership in NAD+ Delivery, Supporting Faster and Safer Treatments Why is the race for intellectual property in the NAD+ market heating up? Niagen Bioscience, Inc. a global…